Form 4: Hims & Hers CLO Sells Shares Under 10b5-1 Plan

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 2,637 shares of Class A Common Stock for $54.38 per share, pursuant to a Rule 10b5-1 trading plan.

Summary

• Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of company stock.
• The transaction involved the disposition of 2,637 shares of Class A Common Stock.
• The shares were sold at a price of $54.38 per share.
• The total value of the shares sold was approximately $143,499.86.
• Following this transaction, Soleil Boughton beneficially owns 161,130 shares of Class A Common Stock.
• The sale was executed on October 13, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on August 28, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this Form 4 reports a routine, pre-scheduled insider stock sale under a Rule 10b5-1 plan, which typically does not reflect new material information or a change in management's immediate outlook on the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. Such filings are standard disclosures for publicly traded companies when executives or directors trade company stock.

Stakeholder Impact

• Shareholders: The sale represents a minor, pre-planned reduction in holdings by a key executive, which is generally not considered a significant indicator of company performance or future prospects.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider stock sale by the Chief Legal Officer, executed under a Rule 10b5-1 plan. Such transactions are typically scheduled in advance and do not inherently signal new material information about the company's financial health or future prospects. Therefore, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it does not alter the fundamental investment thesis for Hims & Hers Health, Inc.

Keywords

Hims & Hers Health, HIMS, Soleil Boughton, Chief Legal Officer, Insider Trading, Stock Sale, Form 4, Rule 10b5-1 Plan, Equity Transaction